Therapeutic drug monitoring of rifapentine in pulmonary tuberculosis patients
PENG Ming-li
CHEN Ming
WEN Xiao-xu
ZHAO Guan-ren
Abstract：Objective: To investigate the clinical necessity of therapeutic drug monitoring (TDM) of rifapentine. Methods: The concentrations of rifapentine were determined by HPLC-MS/MS. The plasma concentrations of rifapentine in 67 pulmonary tuberculosis patients from July 2016 to March 2017 were analyzed. The analysis was carried on the Agilent Poroshell 120SB C18column (4.6 mm × 50 mm, 2.7 μm), ZORBAX SB C18column (2.1 mm×12.5 mm, 5 μm) was used as protection column. The mobile phase was consisted of methanol and 0.2% glacial acetic acid. The flow rate was 0.5 mL·min-1. The gradient elution was as follows: 0.01 - 3.00 min, 25% methanol; 3.01 - 7.00 min, 80% methanol; 7.01 - 10.00 min, 25% methanol. Results: The linear range of rifapentine was 0.60 - 30.00 μg·mL-1(r = 0.996 2). The average recovery was above 90% with RSD below 5%. The peak concentrations of rifapentine were ranged from 1.59 μg·mL-1to 39.79 μg·mL-1. The concentration of rifapentine showed obviously individual difference. Conclusion: There was a definite clinical value for therapeutic drug monitoring of rifapentine.
Keywords：RifapentinePulmonary tuberculosisBlood drug concentrationHPLC-MS/MS
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 81-84 )